Syndax Pharmaceuticals Inc (NASDAQ:SNDX) Expected to Post Earnings of -$0.44 Per Share

Brokerages forecast that Syndax Pharmaceuticals Inc (NASDAQ:SNDX) will announce earnings of ($0.44) per share for the current quarter, according to Zacks. Two analysts have issued estimates for Syndax Pharmaceuticals’ earnings. The lowest EPS estimate is ($0.55) and the highest is ($0.39). Syndax Pharmaceuticals posted earnings per share of ($0.74) during the same quarter last year, which suggests a positive year over year growth rate of 40.5%. The business is expected to report its next quarterly earnings report on Tuesday, August 6th.

According to Zacks, analysts expect that Syndax Pharmaceuticals will report full year earnings of ($1.98) per share for the current financial year, with EPS estimates ranging from ($2.19) to ($1.68). For the next year, analysts expect that the company will post earnings of ($2.06) per share, with EPS estimates ranging from ($2.33) to ($1.57). Zacks Investment Research’s earnings per share calculations are a mean average based on a survey of sell-side research analysts that follow Syndax Pharmaceuticals.

Syndax Pharmaceuticals (NASDAQ:SNDX) last posted its quarterly earnings results on Monday, May 6th. The company reported ($0.53) EPS for the quarter, beating the consensus estimate of ($0.56) by $0.03. The company had revenue of $0.38 million during the quarter, compared to analysts’ expectations of $0.38 million. Syndax Pharmaceuticals had a negative return on equity of 107.48% and a negative net margin of 4,539.55%.



Several analysts have commented on the company. Zacks Investment Research upgraded Garrett Motion from a “sell” rating to a “hold” rating in a report on Friday, May 10th. ValuEngine upgraded Zogenix from a “buy” rating to a “strong-buy” rating in a report on Thursday, June 27th. Finally, HC Wainwright restated a “buy” rating on shares of NioCorp Developments in a report on Tuesday. Two investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the company’s stock. Syndax Pharmaceuticals currently has a consensus rating of “Buy” and a consensus price target of $14.61.

SNDX traded up $0.05 during midday trading on Monday, hitting $9.09. The company’s stock had a trading volume of 49,192 shares, compared to its average volume of 165,848. The company has a current ratio of 6.24, a quick ratio of 6.24 and a debt-to-equity ratio of 0.01. The firm has a market capitalization of $244.95 million, a price-to-earnings ratio of -3.11 and a beta of 2.41. The firm has a 50-day simple moving average of $8.50. Syndax Pharmaceuticals has a 52-week low of $3.39 and a 52-week high of $9.66.

In other news, CEO Briggs Morrison bought 20,400 shares of the firm’s stock in a transaction dated Monday, May 13th. The stock was acquired at an average price of $7.46 per share, for a total transaction of $152,184.00. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. 8.30% of the stock is currently owned by insiders.

Several large investors have recently modified their holdings of SNDX. Campbell & CO Investment Adviser LLC acquired a new position in Syndax Pharmaceuticals in the second quarter valued at about $367,000. SG Americas Securities LLC bought a new stake in shares of Syndax Pharmaceuticals in the first quarter valued at about $55,000. Sofinnova Investments Inc. lifted its holdings in shares of Syndax Pharmaceuticals by 102.2% in the fourth quarter. Sofinnova Investments Inc. now owns 350,110 shares of the company’s stock valued at $1,558,000 after purchasing an additional 176,998 shares in the last quarter. 683 Capital Management LLC lifted its holdings in shares of Syndax Pharmaceuticals by 157.7% in the fourth quarter. 683 Capital Management LLC now owns 1,342,839 shares of the company’s stock valued at $5,976,000 after purchasing an additional 821,839 shares in the last quarter. Finally, Paloma Partners Management Co bought a new stake in shares of Syndax Pharmaceuticals in the fourth quarter valued at about $56,000. Institutional investors and hedge funds own 62.64% of the company’s stock.

Syndax Pharmaceuticals Company Profile

Syndax Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company's lead product candidates include entinostat, which is in Phase III clinical trials for the treatment of advanced hormone receptor positive (HR+) and human epidermal growth factor receptor 2 negative (HER2-) breast cancer; and SNDX-5613 inhibitor that targets the binding interaction of Menin with mixed lineage leukemia-rearranged and acute myeloid leukemia with a mutated nucleophosmin 1.

Featured Article: Does a trade war provide a risk to the global economy?

Get a free copy of the Zacks research report on Syndax Pharmaceuticals (SNDX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Syndax Pharmaceuticals (NASDAQ:SNDX)

Receive News & Ratings for Syndax Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syndax Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.